Yaz Birth Control Pill Most Popular Among Young Women
In the latest Yaz news, a recent study of teenage girls and birth-control habits suggests the oral contraceptive Yaz is more popular with teenage girls and young adults than ever before in spite of the fact that Yaz has increasingly been linked to dangerous side effects.
In the study, released at the end of March by Thomson Reuters, Yaz was named “by far” the most popular oral contraceptive for US women aged 13-18.
The study was based on the behaviors of more than 3 million American women between 2002 and 2009.
Teenage girls also at risk for Yaz side effects
The news comes as evidence mounts that Yaz and similar birth control pills such as Yasmin, Ocella, Zarah, and Gianvi put women, including teenage girls, at a significant risk of developing side effects such as blood clots, pulmonary embolism and gallbladder problems.
Yaz side effects linked to drospirenone
Yaz, Yasmin and their generic counterparts all contain drospirenone, a synthetic progestin linked to a medical condition called hyperkalemia, which can exacerbate side effects associated with all combination oral contraceptives.
Yaz side effects lawsuits continue to grow
Currently, more than 7,000 Yaz and Yasmin lawsuits await trial in US courts, with nearly all involving allegations that drugmaker Bayer Corporation failed to adequately warn users about the risk of side effects. This number continues to grow.
A number of the Yaz lawsuits are wrongful death lawsuits, filed by loved ones with a Yaz lawyer on behalf of young women who have succumbed to fatal Yaz side effects, including pulmonary embolism and strokes.
Pulmonary embolism kills 60,000 Americans every year. It is unclear how many women fall victim every year to Yaz pulmonary embolism.
FDA cited Bayer for inappropriate Yaz marketing
Bayer has been accused of inappropriately marketing Yaz in the United States. In 2008, the company was cited by the FDA for airing television commercials that overstated the birth control pill’s approved indications.
Many young women use Yaz to treat acne, an FDA-approved application of the oral-contraceptive.
According to the Thomson Reuters study, 12 percent of teens aged 13-18 used commercial insurance to pay for oral contraceptives in 2002 versus an increase to 18 percent in 2009. It remains to be seen if this increase in the use of Yaz by young women will result in an increase in Yaz lawsuits.